{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:15:28Z","timestamp":1781702128053,"version":"3.54.5"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Valganciclovir is the only approved antiviral for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation (SOT). Additional approaches may be needed to improve outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicenter retrospective study from 2016 to 2019 was conducted of pediatric SOT recipients in whom at least 3 months of valganciclovir prophylaxis was planned. Episodes of CMV DNA in blood (DNAemia), CMV disease, drug-related toxicities, as well as other infections in the first year posttransplant and demographic and clinical data were collected. CMV DNAemia in the first year after prophylaxis or during prophylaxis (breakthrough) was analyzed by multivariate hazard models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 749 patients enrolled, 131 (17.5%) had CMV DNAemia at any time in the first year; 85 (11.4%) had breakthrough DNAemia, and 46 (6.1%) had DNAemia after prophylaxis. CMV disease occurred in 30 (4%). In a multivariate model, liver transplantation compared to kidney or heart, intermediate or high risk based on donor\/recipient serologies, neutropenia, and valganciclovir dose modifications attributed to toxicity were associated with increased risk of total and\/or breakthrough DNAemia. Bacteremia was also associated with increased hazard ratio for CMV DNAemia. In a separate multivariate analysis, rejection occurred more often in those with breakthrough CMV DNAemia (P = .002); liver transplants, specifically, had increased rejection if CMV DNAemia occurred in the first year (P = .004). These associations may be bidirectional as rejection may contribute to infection risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CMV DNAemia in the first year posttransplantation occurs despite valganciclovir prophylaxis and is associated with medication toxicity, bacteremia, and rejection. Pediatric studies of newer antivirals, especially in higher-risk subpopulations, appear to be warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae353","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T11:18:12Z","timestamp":1719832692000},"source":"Crossref","is-referenced-by-count":10,"title":["Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1628-8446","authenticated-orcid":false,"given":"Marc","family":"Foca","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Children's Hospital at Montefiore, Albert Einstein College of Medicine , Bronx, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5476-0353","authenticated-orcid":false,"given":"Salih","family":"Demirhan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Children's Hospital at Montefiore, Albert Einstein College of Medicine , Bronx, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-7689","authenticated-orcid":false,"given":"Flor M","family":"Munoz","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5976-6612","authenticated-orcid":false,"given":"Kristen G","family":"Valencia Deray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9577-8162","authenticated-orcid":false,"given":"Claire E","family":"Bocchini","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3452-0666","authenticated-orcid":false,"given":"Tanvi S","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9290-6667","authenticated-orcid":false,"given":"Gilad","family":"Sherman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7690-0695","authenticated-orcid":false,"given":"William J","family":"Muller","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital, Northwestern University Feinberg School of Medicine , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-4006","authenticated-orcid":false,"given":"Taylor","family":"Heald-Sargent","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital, Northwestern University Feinberg School of Medicine , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5221","authenticated-orcid":false,"given":"Lara","family":"Danziger-Isakov","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati , Cincinnati, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Blum","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati , Cincinnati, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-780X","authenticated-orcid":false,"given":"Juri","family":"Boguniewicz","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine , Aurora, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8882-6946","authenticated-orcid":false,"given":"Samantha","family":"Bacon","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine , Aurora, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhina","family":"Joseph","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-4267","authenticated-orcid":false,"given":"Jodi","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, Seattle Children's Hospital, University of Washington Medical School , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2853-2581","authenticated-orcid":false,"given":"Monica I","family":"Ardura","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Host Defense, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University , Columbus, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St Jude Children's Research Hospital , Memphis, Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-5399","authenticated-orcid":false,"given":"Gabriela M","family":"Maron","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St Jude Children's Research Hospital , Memphis, Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4008-5507","authenticated-orcid":false,"given":"Jose","family":"Ferrolino","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St Jude Children's Research Hospital , Memphis, Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9974-0786","authenticated-orcid":false,"given":"Betsy C","family":"Herold","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Children's Hospital at Montefiore, Albert Einstein College of Medicine , Bronx, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"2024072916042495700_ofae353-B1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/00007890-199810270-00023","article-title":"Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function","volume":"66","author":"Pescovitz","year":"1998","journal-title":"Transplantation"},{"key":"2024072916042495700_ofae353-B2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/pharmaceutics15010163","article-title":"Optimizing antiviral dosing for HSV and CMV treatment in immunocompromised patients","volume":"15","author":"Huntjens","year":"2023","journal-title":"Pharmaceutics"},{"key":"2024072916042495700_ofae353-B3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"2024072916042495700_ofae353-B4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1399-3046.2010.01330.x","article-title":"The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation","volume":"14","author":"Lapidus-Krol","year":"2010","journal-title":"Pediatr Transplant"},{"key":"2024072916042495700_ofae353-B5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1399-3062.2009.00478.x","article-title":"Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients","volume":"12","author":"Pescovitz","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"2024072916042495700_ofae353-B6","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/TP.0b013e3181a19cda","article-title":"A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients","volume":"87","author":"Madan","year":"2009","journal-title":"Transplantation"},{"key":"2024072916042495700_ofae353-B7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11908-015-0511-8","article-title":"Cytomegalovirus infection in pediatric solid organ transplant recipients: a focus on prevention","volume":"18","author":"Tsai","year":"2016","journal-title":"Curr Infect Dis Rep"},{"key":"2024072916042495700_ofae353-B8","doi-asserted-by":"crossref","first-page":"e13750","DOI":"10.1111\/petr.13750","article-title":"Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis","volume":"24","author":"Das","year":"2020","journal-title":"Pediatr Transplant"},{"key":"2024072916042495700_ofae353-B9","doi-asserted-by":"crossref","DOI":"10.1111\/petr.12879","article-title":"Late cytomegalovirus infection in children: high incidence of allograft rejection and hepatitis in donor negative and seropositive liver transplant recipients","volume":"21","author":"Verma","year":"2017","journal-title":"Pediatr Transplant"},{"key":"2024072916042495700_ofae353-B10","doi-asserted-by":"crossref","first-page":"10121","DOI":"10.3389\/ti.2022.10121","article-title":"Association between cytomegalovirus serostatus, antiviral therapy, and allograft survival in pediatric heart transplantation","volume":"35","author":"Rabbani","year":"2022","journal-title":"Transpl Int"},{"key":"2024072916042495700_ofae353-B11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1600-6143.2004.00451.x","article-title":"Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"2024072916042495700_ofae353-B12","doi-asserted-by":"crossref","first-page":"e13339","DOI":"10.1111\/ctr.13339","article-title":"Cytomegalovirus infection and graft rejection as risk factors for pneumocystis pneumonia in solid organ transplant recipients: a systematic review and meta-analysis","volume":"32","author":"Hosseini-Moghaddam","year":"2018","journal-title":"Clin Transplant"},{"issue":":","key":"2024072916042495700_ofae353-B13","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ajt.2023.07.013","article-title":"Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients","volume":"23","author":"Demirhan","year":"2023","journal-title":"Am J Transplant"},{"key":"2024072916042495700_ofae353-B14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2024072916042495700_ofae353-B15","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2024072916042495700_ofae353-B16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jmoldx.2012.09.007","article-title":"Standard reference material 2366 for measurement of human cytomegalovirus DNA","volume":"15","author":"Haynes","year":"2013","journal-title":"J Mol Diagn"},{"key":"2024072916042495700_ofae353-B17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.biologicals.2016.04.005","article-title":"A collaborative study to establish the 1st WHO international standard for human cytomegalovirus for nucleic acid amplification technology","volume":"44","author":"Fryer","year":"2016","journal-title":"Biologicals"},{"key":"2024072916042495700_ofae353-B18","doi-asserted-by":"crossref","first-page":"e14220","DOI":"10.1111\/petr.14220","article-title":"CMV infection and management among pediatric solid organ transplant recipients","volume":"26","author":"Downes","year":"2022","journal-title":"Pediatr Transplant"},{"key":"2024072916042495700_ofae353-B19","doi-asserted-by":"crossref","first-page":"e13232","DOI":"10.1111\/tid.13232","article-title":"Evaluation of a change in cytomegalovirus prevention strategy following pediatric solid organ transplantation","volume":"22","author":"Pangonis","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"2024072916042495700_ofae353-B20","doi-asserted-by":"crossref","first-page":"e13568","DOI":"10.1111\/petr.13568","article-title":"Impact of standardized protocols for cytomegalovirus disease prevention in pediatric solid organ transplant recipients","volume":"23","author":"Ganapathi","year":"2019","journal-title":"Pediatr Transplant"},{"key":"2024072916042495700_ofae353-B21","doi-asserted-by":"crossref","first-page":"e14493","DOI":"10.1111\/petr.14493","article-title":"Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis","volume":"27","author":"Liverman","year":"2023","journal-title":"Pediatr Transplant"},{"key":"2024072916042495700_ofae353-B22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/ajt.16822","article-title":"Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients","volume":"22","author":"Valencia Deray","year":"2022","journal-title":"Am J Transplant"},{"key":"2024072916042495700_ofae353-B23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa011759","article-title":"A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis","volume":"346","author":"Martin","year":"2002","journal-title":"N Engl J Med"},{"key":"2024072916042495700_ofae353-B24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00042560-200208010-00004","article-title":"A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis","volume":"30","author":"Lalezari","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024072916042495700_ofae353-B25","doi-asserted-by":"crossref","first-page":"e5512","DOI":"10.1371\/journal.pone.0005512","article-title":"Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy","volume":"4","author":"Kalil","year":"2009","journal-title":"PLoS One"},{"key":"2024072916042495700_ofae353-B26","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1086\/597089","article-title":"Infectious complications of antilymphocyte therapies in solid organ transplantation","volume":"48","author":"Issa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024072916042495700_ofae353-B27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases\u2014diversity, plasticity and therapeutic opportunities","volume":"18","author":"Wen","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2024072916042495700_ofae353-B28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/TP.0000000000002396","article-title":"Clinical correlation of cytomegalovirus infection with CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients","volume":"103","author":"Meesing","year":"2019","journal-title":"Transplantation"},{"key":"2024072916042495700_ofae353-B29","doi-asserted-by":"crossref","first-page":"e14714","DOI":"10.1111\/petr.14714","article-title":"Evaluation of valganciclovir's neutropenia risk in pediatric solid organ transplant recipients utilizing two dosing regimens","volume":"28","author":"Patel","year":"2024","journal-title":"Pediatr Transplant"},{"key":"2024072916042495700_ofae353-B30","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2024072916042495700_ofae353-B31","doi-asserted-by":"crossref","first-page":"62.e1","DOI":"10.1016\/j.jtct.2022.10.005","article-title":"Letermovir as cytomegalovirus prophylaxis in a pediatric cohort: a retrospective analysis","volume":"29","author":"Kuhn","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":":","key":"2024072916042495700_ofae353-B32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41409-024-02209-2","article-title":"Letermovir for cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP)","volume":"59","author":"Galaverna","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2024072916042495700_ofae353-B33","doi-asserted-by":"crossref","first-page":"e30608","DOI":"10.1002\/pbc.30608","article-title":"Letermovir for cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation","volume":"70","author":"Chen","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"2024072916042495700_ofae353-B34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40272-022-00547-6","article-title":"Letermovir for prophylaxis and pre-emptive therapy of cytomegalovirus infection in paediatric allogeneic haematopoietic cell transplant patients","volume":"25","author":"K\u00f6rholz","year":"2023","journal-title":"Paediatr Drugs"},{"key":"2024072916042495700_ofae353-B35","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.21873\/anticanres.15848","article-title":"Letermovir prophylaxis for cytomegalovirus infection in children after hematopoietic cell transplantation","volume":"42","author":"Richert-Przygonska","year":"2022","journal-title":"Anticancer Res"},{"key":"2024072916042495700_ofae353-B36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"2024072916042495700_ofae353-B37","author":"US Food and Drug Administration. Drug databases: letermovir"},{"issue":":","key":"2024072916042495700_ofae353-B38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0000000000004208","article-title":"Pharmacokinetics, safety, and efficacy of letermovir for cytomegalovirus prophylaxis in adolescent hematopoietic cell transplantation recipients","volume":"43","author":"Groll","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"2024072916042495700_ofae353-B39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0966-3274(99)80023-9","article-title":"Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms","volume":"7","author":"Borchers","year":"1999","journal-title":"Transpl Immunol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae353\/58376689\/ofae353.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/7\/ofae353\/58650919\/ofae353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/7\/ofae353\/58650919\/ofae353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:03:22Z","timestamp":1722297802000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae353\/7702092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,6,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae353","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,6,28]]},"article-number":"ofae353"}}